Cofepris carried out an investigation after a complaint from Laboratorios Grossman, which markets these products, about the illegal sale of both drugs
The Federal Commission for the Protection against Sanitary Risks (Cofepris) of the alerted this Friday about the illegal marketing of counterfeit products Ivermectin and Ivermin, which, it is presumed, could be useful against the COVID-19.
The agency issued a health alert in a statement, in which it reported that an investigation was carried out after a complaint of Grossman Laboratories, which markets these products, on the illegal sale of both drugs.
Grossman Laboratories carried out a comparative analysis of the products and concluded that they are counterfeit ”, specified Cofepris.
He indicated that Ivermectin has the distinctive name: IVEXTERM, with Sanitary Registration 566M2001 SSA IV, cardboard box presentation with 2, 4, 6 or 100 tablets.
This medicine has an authorized therapeutic indication for: Scabicidal, Pediculicidal, Oxyuriasis, Ascariasis, Hookworms and Trichuriasis.
While the falsified ones have the name of Ivermectin, with lot number 382820, and an expiration date of December 22, 2022, in addition to not having a sanitary registration.
Meanwhile, the Ivermin has the batch number SC2025 printed with an expiration date of June 2023 and has the health registration 566M2001 SSA IV, the same as the original.
Ivermectin is an antiparasitic drug used against river blindness, lymphatic filariasis, and other neglected tropical diseases.
It also has some antiviral effect against single-stranded RNA viruses such as dengue and yellow fever.
In early April, researchers from Australia reported that ivermectin inhibits the replication of SARS-CoV-2 in vitro, so users on social networks spread unproven information to encourage their consumption.
Cofepris recommended that the general population review the product before purchasing it and, in case of identifying any of the indicated irregularities, it is preferable not to buy it.
If you already have it and suspect that it is a fake product, it will be better to suspend its use and make the health report on the agency’s website, for which it is required to have the purchase receipt of the product at hand.
While in hospitals, pharmacies and points of sale, he asked to check their stocks and in case of finding the referred products or any other that generates doubt about their authenticity, he must immobilize it and notify Cofepris.
He also asked to report any adverse reaction or discomfort related to the use or consumption of the product on the agency’s website.
With information from .